Tyrosine kinase inhibitors-ZD1839 (Iressa)

Current Opinion in Oncology

Volumn 13, Issue 6, 2001, Pages 491-498

  Arteaga, Carlos L ^a   Johnson, David H ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Division of Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; LIGAND; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CELL PROLIFERATION; CELL VIABILITY; DISEASE ASSOCIATION; ENZYME INHIBITION; EPITHELIUM TUMOR; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CLINICAL TRIALS; DISEASE PROGRESSION; DOGS; ENZYME INHIBITORS; HUMANS; LIGANDS; LUNG NEOPLASMS; NEOPLASMS; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0034758726     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200111000-00012     Document Type: Review

References (34)

1. Signaling-2000 and beyond
2. Untangling the ErbB signaling network
3. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
4. Epidermal growth factor-related peptides and their receptors in human malignancies
5. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
6. The epidermal growth factor receptor and its inhibition in cancer therapy
7. Development of inhibitors for protein tyrosine kinases
8. Overview of the rationale and clinical trials with signal transduction inhibitors in lung cancer
9. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases
10. The epidermal growth factor receptor and its inhibition in cancer therapy
11. Epidermal growth factor receptor tyrosine kinase inhibitors as articancer agents
12. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
13. ZD1839 ('Iressa') as an anticancer agent
14. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
15. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB-2) overexpressng breast tumor cells
16. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
17. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
18. Inhibition of growth factor production and argiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
19. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
21. Epidermal growth factor receptor family and chemosensitization
22. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells
23. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
24. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibodies
25. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
26. ZD1839 (Iressa), an oral EGFR·TKI (epidermal growth factor receptor tyrosine kinase inhibitor): Pharmacokinetic results of a phase I study in patients with advanced cancer
27. Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
28. Final results of a phase I intermittant dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with various solid tumors
29. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer
30. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
31. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI·774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
32. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition In situ and antitumor effects in athymic mice
33. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases
34. Objective regressions in non-small cell lung cancer patients treated in phase I trials of ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)